James Murray MP: speeches

James Murray MP: full overview

4 Jul 2025–3 Jul 2026

How these years work

Our reporting years run from 4 July to 3 July, starting with the 2024 general election. They are not official parliamentary sessions. Office costs keep IPSA’s April–March financial years. Records may cover only part of a year; a missing record does not mean no work was done.

Compare reporting years, sessions and IPSA financial years.

Parliamentary contributions: dates and coverage

Source checked
19 Nov 2026
Last successful import
19 Nov 2026
Records dated through
18 Nov 2026
Selected period
Reporting year 2: 4 Jul 2025 to 3 Jul 2026
Completeness
Published snapshot: 20,988 records in the source window 21 Aug 2026 to 19 Nov 2026. The published snapshot covers its stated source window. Older imports can extend beyond it; not every public speech is included.

How to read these datesOfficial source

This page lists the parliamentary spoken contributions we hold for James Murray in the reporting year 2 (4 Jul 2025 to 3 Jul 2026). It does not include every public speech, party-conference address or constituency event. Latest retained contribution in this period: 30 Jun 2026. The source check date and dataset limits are shown above. Open the Hansard link for the full debate and surrounding context.

Clear speech filters

Read what this MP said, asked and contributed in Parliament.

410 published records · newest first.

Speeches

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    I reassure the hon. Lady, as I set out in my responses to earlier questions, that while my starting point is that clinical evidence should be the basis for our way forward, I have taken the responsibility to interrogate that with the highest level of scrutiny in order to ensure that the conclusions are as robust as possible.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    There is a fundamental difference of approach between me and the hon. Lady. The reason for the trial is not to ensure that young people on the waiting list can get access to treatment; the trial is to find an evidence base on which to take future decisions about whether young people should be offered treatment and, if so, in what way.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    I thank the right hon. Gentleman for his comments, and although he and I come to a different conclusion on this, I do not doubt for a second the sincerity of his motivation in wanting to protect children and young people. I actually agree with him, as I said in my earlier comments, that most young children who are questioning their gender will resolve it on their own—let them be to resolve it.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    I thank the hon. Lady for her question, which highlights the importance we all place on making sure that vulnerable children are protected in the way that the trial proceeds. Perhaps I can offer her some detail which might reassure her by explaining who is on the national multidisciplinary team. As I mentioned earlier, the national multidisciplinary team will have to give permission for young people to be involved in the trial, as will the NHS care team.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    I am sure that the hon. Lady will agree that this is now one of the most heavily scrutinised clinical trials in this country in recent history, and rightly so—it is right that it is so heavily scrutinised and that we all seek assurances about the safeguards in place. It is right that, as Health Secretary, I made sure that I got those detailed safeguards before coming to the House to set out the Government’s position today. The hon.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    As my hon. Friend will know, the recommendations in Dr Hilary Cass’s review set out how to establish better services for young people in the future. The focus of today’s statement, the clinical trial, is just one part of the wider work on how best to support young people who need extra support in this situation.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    Despite our different conclusions on this matter, I respect my hon. Friend. Part of taking decisions as Health Secretary involves sometimes approaching issues where one might feel uncomfortable on a personal level, but none the less being guided by the right principles in order to take decisions for other groups of people in the country and for the country as a whole.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    Although the hon. Gentleman comes to a different conclusion from the one that I and the Government have come to, he poses the right question when he asks what harm do we need to protect against while getting clinical evidence.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    Dr Cass has raised that point a number of times, particularly when she has spoken in public and been interviewed on her concerns about young people accessing equivalent drugs through an unregulated source—through online sources that are not carefully controlled and where there is no monitoring of the effects on young people. That is part of her motivation for recommending the approach that she proposes.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    With your permission, Madam Deputy Speaker, I shall make a statement on the Pathways trial. I know what a sensitive, emotive and difficult issue this is. I myself have wrestled with, and at times struggled with, the profound challenges that this subject raises. In all of my consideration and deliberation over this matter, my bottom line has been to protect the safety and wellbeing of children and young people.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    My hon. Friend asks about the data linkage study, and I apologise to my hon. Friend the Member for North Northumberland (David Smith), who a few seconds ago also asked about that—I did not respond then but can now address both questions together.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    The hon. Lady is right to draw attention to some of the gateways that children and young people will have to go through before being accepted on to the trial.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    The hon. Lady refers, apparently with some certainty, to what she considers to be the clinical outcomes of these puberty blockers on young people. I have to say, with all due respect, that I would trust Dr Cass’s conclusion more than the hon. Lady’s, which is that there is not evidence about the risks or benefits of these medications.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    My hon. Friend raises an important point about the relationship between politics and clinical evidence and clinically led decisions. Being led by clinical advice and clinical evidence is a decision that I and this Government stand behind.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    I thank the hon. Lady for her remarks, and for her tone and approach to this sensitive matter. Sadly, we have waiting lists across many different parts of the NHS. This Government are determined to deal with that so that everyone can receive the appropriate treatment. There are wider questions, which we could debate at another time, about the support that children who are questioning their identity might need.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    I agree with the shadow Minister that most children and young people who are questioning their identity and gender are likely to resolve those questions on their own, and I think Dr Cass would agree with that. As I said in my opening remarks, for the majority of children who question their gender, we should let them be; they will resolve the matter through their friends and family and their own development.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    This trial has been paused since earlier this year while the MHRA worked to strengthen the safeguards. Those stronger safeguards are now in place, which gives greater protection to young people who are involved in this trial. As I mentioned in my remarks earlier, one of my responsibilities as Health Secretary is to interrogate the detail to ensure that safeguards are adequate.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    I absolutely agree with my hon. Friend about the importance of following clinical evidence and taking a clinically led and evidence-based approach to this decision.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Hansard source
    More

    The reason for having this trial is to establish whether there are in fact benefits to this treatment for some children and young people as well as what the risks of harm are. I believe it is right, on balance, to proceed with this clinical trial to get clinical evidence on the basis of having the highest possible protections against a greater risk of harm to children and young people involved in this trial.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    The number of expected participants in the trial is 226. That is not a firm target—it does not have to be exactly that number—but that is the number at which statistically significant conclusions can be drawn. The 226 will fall into two camps: one will access the medical treatment immediately and the other will access it after one year.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    I welcome the fact that the hon. Lady agrees with the Government that we should base our decisions about whether and how to provide support for children, particularly in the case of the treatment that is at the centre of this clinical trial, on clinical evidence and the expert advice of clinicians.

  • 22 Jun 2026 · Pathways Study: Puberty Suppression · Read the full contribution in Hansard
    More

    We are following clinical advice. We are ensuring that there is a triple lock on the consent for children and young people to be involved in this trial, involving the consent or assent of the young person themselves, parents or guardians, and the NHS care team—the national multidisciplinary team that I mentioned earlier.

  • 9 Jun 2026 · Health Services for Men · Read the full contribution in Hansard
    More

    Let me be really clear in my advice to any man who is worried about prostate cancer, whether he has symptoms or not: go and discuss it with your GP. Testing is available when GPs recommend it, and I would recommend to no man that he should worry about it in silence, sit at home and fret about what might be going on.

  • 9 Jun 2026 · Health Services for Men · Hansard source
    More

    Too many men lead too much of their lives in poor health and face barriers to access to health services. We have published England’s first ever men’s health strategy to get men speaking about their physical and mental health, and we are getting on with implementing it. From partnering with the Premier League to investing in the men’s health community fund, we are meeting men where they are, and helping them to lead longer, healthier lives.

  • 9 Jun 2026 · Topical Questions · Hansard source
    More

    The hon. Member for Surrey Heath can rest assured that this Government are focused on the new hospitals programme, which is now credible and deliverable after what we inherited from the previous Government, and that we will get those hospitals in place.

Explore activity by topic or department

Contributions by debate topic

4 Jul 2025–3 Jul 2026. Existing keyword taxonomy applied to official debate titles and contributions; a contribution may appear in more than one topic and unclassified records are retained.

View as listCommunities and local government: 25Communities and local government25Culture, media and sport: 18Culture, media and sport18Defence and foreign affairs: 13Defence and foreign affairs13Democracy and constitution: 31Democracy and constitution31Economy and business: 212Economy and business212Education and skills: 10Education and skills10Environment and energy: 24Environment and energy24Health and care: 163Health and care163Housing and planning: 14Housing and planning14Immigration and borders: 2Immigration and borders2Justice and policing: 18Justice and policing18Social security and pensions: 39Social security and pensions39Transport: 15Transport15Unclassified: 48Unclassified48
What this shows and doesn't show
4 Jul 2025–3 Jul 2026. Existing keyword taxonomy applied to official debate titles and contributions; a contribution may appear in more than one topic and unclassified records are retained. Published records do not measure effort or effectiveness. Methodology.
Department or topicPublished records
Communities and local government25
Culture, media and sport18
Defence and foreign affairs13
Democracy and constitution31
Economy and business212
Education and skills10
Environment and energy24
Health and care163
Housing and planning14
Immigration and borders2
Justice and policing18
Social security and pensions39
Transport15
Unclassified48

Published records only — not a full account of an MP’s work. How we work →